The AGIR program overview
AGIR, a platform dedicated to the search for unprecedented antibiotic structures from rare bacterial strains
The AGIR program aims to systematically explore biodiversity, mainly rare micro-organisms in order to identify and develop a portfolio of drug candidates, and then develop these candidates through agreements with pharmaceutical companies.
DEINOVE believes that the extraordinary diversity of life, still largely unexplored, is the key to discover new anti-infective agents with innovative structures capable of overcoming bacterial resistance.
While the world lacks new antibiotics, research is still predominantly focused on a small number of micro-organisms of interest or on the construction by chemical synthesis of molecules derived from existing drugs.
The AGIR program is developing new methods of collection, culture, evaluation of the antibiotic potential of rare bacterial strains, and the optimization of molecules.
Through its expertise, DEINOVE has already identified several strains of interest in its own bacterial library and has discovered a new antibiotic structure for which two patent applications have been filed. Other compounds, derived from new strains or derivatives of this first molecule, are under study.
The AGIR program was selected in 2017 by the Investments for the Future Program and receives financial support of €14.6m over 5 years for a total investment of €25m. This financing materializes the commitment of the French public authorities in the fight against resistance to antibiotics, a major health issue on a global scale.
An ambitious collaborative project
Strengthened by targeted strategic partnerships to broaden the scope of research
Capitalizing on its technology that allows it to automate and accelerate the analysis of large quantities of strains, DEINOVE aims to maximize the opportunities to discover new antibiotic structures by expanding its field of research beyond its own bacterial library. To date, the Company has entered into partnerships with two companies with portfolios of various strains collected as part of their pharmaceutical activities:
- Naicons: An Italian biopharmaceutical company also specialized in the search for innovative antibiotics, NAICONS has a collection of 45 000 microbial strains. Initially, DEINOVE will have access to 400 strains carefully selected for their potential and will use the power of its robotic technology platform to detect and characterize the antibiotic activities of these strains. In case of discovery of a strain of interest, DEINOVE may acquire it either via a commercial license or full ownership, to initiate the development of drug candidates.
- bioMérieux: Specializing in the field of infectious disease diagnosis, bioMérieux has one of the largest bacterial libraries in the world. As a first step, bioMérieux will provide DEINOVE with more than 250 strains of 130 different species. DEINOVE and bioMérieux have jointly selected the strains for this project with the aim of biological diversity.